Date Filed | Type | Description |
06/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/15/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
03/21/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/01/2023 |
8-K
| Completion of Acquisition or Disposition of Assets, Departure of Directors or Certain Officers; Election of Directors; Appoin... |
01/11/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
01/05/2023 |
PRER14A
| Form PRER14A - Preliminary Proxy Soliciting materials: |
12/22/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
11/16/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
06/29/2022 |
8-K
| Quarterly results |
05/16/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
04/28/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
03/31/2022 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
03/14/2022 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
12/22/2021 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
11/29/2021 |
4
| Sternberg Stuart (10% Owner) has filed a Form 4 on AMERICAN BIO MEDICA CORP |
11/18/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
11/18/2021 |
8-K
| Quarterly results
Docs:
|
"ABMC REPORTS THIRD QUARTER 2021 RESULTS Kinderhook, N.Y., November 18, 2021 – American Bio Medica Corporation today announced financial results for the three and nine months ended September 30, 2021. Chief Executive Officer Melissa A. Waterhouse stated, “We are encouraged by the fact that when compared to the second quarter 2021, sales actually increased 16.1% in the third quarter 2021. This increase is a result of our drug testing markets continuing to return to normal, increased contract manufacturing sales from our current customers, stabilized clinical sales and higher sales of rapid Covid-19 tests as a result of new products we started to offer within the last few months. At the end of the third quarter, we had open sales orders of ABMC drug tests in the amount of $336,000 due to cont..." |
|
10/26/2021 |
SC 13G/A
| Sternberg Stuart reports a 10.1% stake in AMERICAN BIO MEDICA CORPORATION |
10/26/2021 |
3
| Sternberg Stuart (10% Owner) has filed a Form 3 on AMERICAN BIO MEDICA CORP |
08/18/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
08/18/2021 |
8-K
| Quarterly results |
08/16/2021 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
07/26/2021 |
SC 13D
| MORONEY JOHN J reports a 4.9% stake in * AMERICAN BIO MEDICA CORPORATION |
07/19/2021 |
4
| MORONEY JOHN J (6.17% OWNER) has filed a Form 4 on AMERICAN BIO MEDICA CORP
Txns:
| Sold 495,500 shares
@ $0.061, valued at
$30.2k
|
|
06/29/2021 |
8-K
| Quarterly results |
06/01/2021 |
SC 13D
| MORONEY JOHN J reports a 6.2% stake in AMERICAN BIO MEDICA CORPORATION |
05/20/2021 |
10-Q
| Quarterly Report for the period ended March 31, 2021 |
05/20/2021 |
8-K
| Quarterly results |
05/17/2021 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
05/04/2021 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/23/2021 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
04/15/2021 |
10-K
| Annual Report for the period ended December 31, 2020 |
04/15/2021 |
8-K
| Quarterly results |
|